RATIONALE: Augmentation therapy with serotonin-1A receptor (5-HT1A) partial agonists has been suggested to ameliorate psychotic symptoms in patients with schizophrenia. OBJECTIVE AND METHODS: The objective of the present study was to examine the effect of repeated administration of tandospirone (0.05 and 5 mg/kg) on locomotor activity in a novel environment and on sensorimotor gating in rats treated with the N-methyl-D-aspartate receptor antagonist MK-801, which has been used in animal models of schizophrenia. Furthermore, we sought to determine whether the effect of tandospirone on these behavioural measures is blocked by WAY 100635 (0.3 mg/kg), a 5-HT1A receptor antagonist, and whether there is an interaction between haloperidol (0.1 mg/kg; a dopamine-D2 receptor antagonist) and tandospirone. RESULTS: Tandospirone at 5 mg/kg, but not 0.05 mg/kg, decreased locomotor activity in saline or MK-801-treated rats, which were not affected by co-treatment with WAY 100635. Haloperidol decreased locomotion both in saline and MK-801-treated animals, and this effect was not evident in the latter group receiving the higher dose of tandospirone. Tandospirone (5 mg/kg)-induced disruption of sensorimotor gating in saline or MK-801-treated animals was reversed by WAY-100635, but not by haloperidol. CONCLUSIONS: These findings suggest that behavioural changes induced by tandospirone are not fully blocked by 5-HT1A antagonists and that tandospirone (5 mg/kg) potentiates the effect of MK-801. Overall, these findings point to an interaction between NMDA and 5-HT(1A) receptors. Part of the effect of tandospirone on locomotor activity may be mediated by the actions of its active metabolites on other neurotransmitter systems.

Department of Brain Pathophysiology and Biochemistry Prague Psychiatric Centre Prague Czech Republic

Zobrazit více v PubMed

Neuropharmacology. 2007 Mar;52(4):1071-8 PubMed

Neurosci Biobehav Rev. 2008 Jul;32(5):1014-23 PubMed

Prog Neurobiol. 1999 Oct;59(2):107-28 PubMed

Psychopharmacology (Berl). 2007 Sep;193(4):521-37 PubMed

Schizophr Bull. 2010 Mar;36(2):246-70 PubMed

Adv Ther. 2008 Oct;25(10):1037-56 PubMed

Life Sci. 1998;63(14):1221-6 PubMed

Biol Psychiatry. 1990 Jul 15;28(2):99-109 PubMed

Neurosci Lett. 1991 Nov 11;132(2):179-82 PubMed

J Chromatogr. 1982 Dec 3;252:310-4 PubMed

Neuropharmacology. 1983 Mar;22(3):273-8 PubMed

Int J Neuropsychopharmacol. 2009 Oct;12(9):1249-59 PubMed

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jul 1;32(5):1302-7 PubMed

Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):965-7 PubMed

Eur Neuropsychopharmacol. 2007 Oct;17(10):643-50 PubMed

Psychopharmacology (Berl). 2002 Aug;163(1):85-94 PubMed

Curr Opin Pharmacol. 2007 Feb;7(1):48-55 PubMed

J Neurosci. 1983 Apr;3(4):733-8 PubMed

Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):1061-6 PubMed

Am J Psychiatry. 2001 Oct;158(10):1722-5 PubMed

Clin Drug Investig. 2004;24(2):121-6 PubMed

Pol J Pharmacol Pharm. 1989 Jan-Feb;41(1):51-61 PubMed

Biol Psychiatry. 2001 May 15;49(10):861-8 PubMed

Gen Pharmacol. 1995 Dec;26(8):1765-72 PubMed

Mol Pharmacol. 2007 Apr;71(4):1030-9 PubMed

Naunyn Schmiedebergs Arch Pharmacol. 1998 Aug;358(2):197-206 PubMed

Pharmacol Biochem Behav. 2005 Apr;80(4):591-6 PubMed

Arch Gen Psychiatry. 2006 Dec;63(12):1325-35 PubMed

Psychopharmacology (Berl). 2001 Oct;157(4):388-94 PubMed

J Clin Psychopharmacol. 1992 Oct;12(5):341-5 PubMed

Am J Psychiatry. 2001 Sep;158(9):1367-77 PubMed

Life Sci. 2003 Feb 28;72(15):1665-82 PubMed

J Pharmacol Sci. 2009 Apr;109(4):593-9 PubMed

J Pharmacol Exp Ther. 2007 Mar;320(3):1224-36 PubMed

J Clin Psychopharmacol. 2000 Jun;20(3):386-8 PubMed

J Neurosci. 2005 Jun 8;25(23):5488-501 PubMed

Pharmacol Toxicol. 1993 Jun;72(6):398-406 PubMed

Life Sci. 1991;48(18):1779-86 PubMed

Eur Neuropsychopharmacol. 2006 Jul;16(5):376-82 PubMed

Schizophr Res. 2007 Sep;95(1-3):158-68 PubMed

Psychopharmacology (Berl). 2005 Jul;180(3):491-500 PubMed

Neurosci Biobehav Rev. 2002 Jan;26(1):1-11 PubMed

J Pharmacol Exp Ther. 1996 Aug;278(2):752-62 PubMed